Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

GH Research PLC

Healthcare US GHRS

23.25USD
-1.18(4.83%)

Last update at 2026-06-04T20:00:00Z

Day Range

23.0825.31
LowHigh

52 Week Range

8.7524.66
LowHigh

Fundamentals

  • Previous Close 24.43
  • Market Cap1280.91M
  • Volume274081
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-60.59900M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.79

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -48.25800M -38.96100M -35.58700M -22.45600M -9.20200M
Minority interest - - - - -
Net income -48.25800M -38.96100M -35.58700M -7.13500M -9.21100M
Selling general administrative 21.65M 15.00M 11.12M 10.07M 6.55M
Selling and marketing expenses - 0.04M 0.10M - -
Gross profit -0.33500M -0.31500M -0.31500M - -
Reconciled depreciation 0.34M 0.32M 0.32M 0.05M 0.02M
Ebit -60.67600M -38.91300M -35.52400M -30.55400M -15.10000M
Ebitda -60.34100M -38.59800M -35.20900M -37.73000M -15.08100M
Depreciation and amortization 0.34M 0.32M 0.32M -7.17600M 0.02M
Non operating income net other - - - - -
Operating income -60.67600M -50.31200M -41.22200M -30.55400M -15.10000M
Other operating expenses 60.68M 50.31M 41.22M 30.55M 15.10M
Interest expense 0.46M 0.72M 0.72M 8.10M 0.00900M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M -
Interest income 5.08M 6.28M 8.98M 0.86M -
Net interest income 4.62M 5.56M 8.26M 0.92M -0.00900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.00000M -15.32100M 0.00900M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 60.34M 50.31M 41.22M 30.55M 15.10M
Cost of revenue 0.34M 0.32M 0.32M - -
Total other income expense net 12.42M 11.35M 5.63M 8.10M 5.90M
Discontinued operations - - - - -
Net income from continuing ops -48.25800M -38.96100M -35.58700M -22.45600M -9.20200M
Net income applicable to common shares - - - -22.45600M -9.20200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 288.23M 188.27M 226.30M 254.36M 279.92M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.97M 3.17M 2.53M 2.59M 0.01000M
Total liab 8.53M 9.32M 6.70M 4.55M 2.75M
Total stockholder equity 279.70M 178.95M 218.97M 249.82M 277.18M
Deferred long term liab - - - - -
Other current liab 8.02M 8.70M 6.36M 2.68M 1.87M
Common stock 1.55M 1.30M 1.30M 1.30M 1.30M
Capital stock 1.55M 1.30M 1.30M 1.30M 1.30M
Retained earnings -154.42500M -106.44600M -67.94000M -32.49300M -10.03700M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 246.25M 100.79M 78.42M 165.96M 276.78M
Cash and equivalents - - - - -
Total current liabilities 8.38M 8.95M 6.70M 4.55M 2.75M
Current deferred revenue - - -3.49000M - -
Net debt -245.73900M -100.16700M -78.07700M -165.95500M -276.77600M
Short term debt 0.36M 0.26M 0.34M - -
Short long term debt - - - - -
Short long term debt total 0.51M 0.62M 0.34M - -
Other stockholder equity 431.06M 291.46M 292.76M 291.45M 291.45M
Property plant equipment - - - 0.10M 0.08M
Total current assets 285.98M 154.22M 164.09M 168.54M 279.84M
Long term investments 0.00000M 33.30M 61.14M 85.72M -
Net tangible assets - - - 249.82M 277.18M
Short term investments 34.46M 48.53M 83.14M - -
Net receivables 1.29M 1.73M 0.18M 0.09M 0.05M
Long term debt - - - - -
Inventory - - -0.17800M -0.09000M 3.01M
Accounts payable 3.77M 3.74M 3.49M 1.87M 0.88M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.52M -7.36700M -10.50700M -10.44000M -5.53700M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.63M - - - -
Deferred long term asset charges - - - - -
Non current assets total 2.25M 34.05M 62.21M 85.82M 0.08M
Capital lease obligations 0.51M 0.62M 0.97M - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 46.29M 65.14M -54.10000M -84.68800M -0.10400M
Change to liabilities - - - 0.00000M 0.00000M
Total cashflows from investing activities 46.17M 65.14M -54.10000M -84.68800M -0.10400M
Net borrowings -0.19700M -0.30400M -0.21900M - -
Total cash from financing activities 139.65M -0.30400M -0.20400M 0.00000M 286.45M
Change to operating activities - - - 2.16M -0.55900M
Net income -48.25800M -38.96100M -35.58700M -22.45600M -9.20200M
Change in cash 145.46M 22.37M -87.53500M -110.82100M 270.88M
Begin period cash flow 100.79M 78.42M 165.96M 276.78M 5.89M
End period cash flow 246.25M 100.79M 78.42M 165.96M 276.78M
Total cash from operating activities -43.55200M -42.28500M -33.33600M -26.19900M -15.28300M
Issuance of capital stock 150.00M 0.00000M 0.01M 0.00000M 309.20M
Depreciation 0.34M 0.32M 0.32M 0.05M 0.02M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.19700M -0.30400M -54.10000M -84.68800M -22.75300M
Change to netincome - - - -5.94900M -5.54100M
Capital expenditures 0.12M 0.05M 0.10M 0.07M 0.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.09400M 0.19M 1.65M 2.16M -0.55900M
Stock based compensation 8.50M 1.17M 2.29M 1.67M 0.37M
Other non cash items 7.46M -4.99800M -2.00000M -7.62000M 0.00900M
Free cash flow -43.67300M -42.33400M -33.43600M -26.26600M -15.38700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
GHRS
GH Research PLC		 -1.18 4.83% 23.25 - - - 4.57 -11.9745
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

GH Research PLC

Joshua Dawson House, Dublin, Ireland, D02 RY95

Key Executives

Name Title Year Born
Mr. Florian Schonharting M.Sc. (Econ) Co-Founder & Non-Exec. Chairman 1969
Mr. Theis Terwey M.D. Co-Founder & CEO 1977
Mr. Magnus Halle Co-Founder & MD of Ireland 1998
Ms. Julie Ryan A.C.A. VP of Fin. 1986
Mr. Florian Schonharting M.Sc. (Econ) Co-Founder & Non-Executive Chairman of the Board 1969
Dr. Theis Terwey M.D. Co-Founder & CEO 1976
Mr. Magnus Halle Co-Founder & MD of Ireland 1997
Ms. Julie Ryan F.C.A. Vice President of Finance 1986
Mr. Aaron Cameron M.B.A. Chief Operating Officer 1985
Mr. Naoise Gaffney VP & Head of Intellectual Property NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions